Quantcast

Januvia Lawsuits Being Investigated by Bernstein Liebhard LLP, as Federal Panel Set to Decide on Consolidation of Januvia Pancreatic Cancer Claims

July 21, 2013

The Firm is investigating Januvia lawsuits on behalf of patients who took Januvia and were diagnosed with pancreatitis, pancreatic cancer or thyroid cancer.

New York, New York (PRWEB) July 21, 2013

Bernstein Liebhard LLP is investigating Januvia lawsuit claims on behalf of individuals who were treated with this Type 2 diabetes drug, and later developed pancreatitis, pancreatic cancer or thyroid cancer. Type II diabetics who took Januvia and who were diagnosed with one of these diseases may be entitled to compensation for medical bills, lost wages, pain and suffering and other damages.

“Recent studies, as well action by the U.S. Food & Drug Administration (FDA), have raised awareness about the serious side effects that may be associated with the use of Januvia. We have received numerous inquiries regarding Januvia lawsuits from users of this drug who have been diagnosed with pancreatitis, pancreatic cancer or thyroid cancer,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to alleged victims of Januvia side effects.

Januvia Lawsuit

Januvia and other diabetes drugs in a class called incretin mimetics reduce blood sugar by stimulating insulin production by the pancreas. The FDA announced in March that it was investigating Januvia and other incretin mimetics after results from a small study indicated these medications might cause pre-cancerous changes in the cells of the pancreas.* A month later, the Institute for Safe Medicine Practices (ISMP) published an analysis of the FDA adverse even database which revealed that during the 12 month period ending in June 2012, the agency had received reports of 177 possible cases of pancreatitis,18 cases of pancreatic cancer, and a single case of thyroid cancer in Januvia patients. According to the ISMP, the analysis revealed that, as a class, incretin mimetics were 25 times more likely to be linked to pancreatic cancer compared to other diabetes drugs.** Most recently, a report published June 10th in the British Medical Journal revealed previously unpublished data that indicated the manufacturers of incretin mimetics may have downplayed the drugs’ potential to harm the pancreas.***

Court records indicate that Januvia and other incretin mimetics have been named in at least 53 lawsuits that allege the drugs caused pancreatic cancer. On July 25, the U.S. Judicial Panel on Multidistrict Litigation (JPML) will hear Oral Arguments regarding the possible consolidation of all incretin mimetic lawsuits in a single federal court for pretrial proceedings. On April 29th, 2013, Merck & Co., the maker of Januvia, voiced support for the establishment of such a litigation, and agreed that the most appropriate venue for the proceeding is the U.S. District Court, Southern District of California. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)

Patients who have developed pancreatic cancer, thyroid cancer or pancreatitis allegedly due to Januvia may be entitled to compensation. To learn more about filing a Januvia lawsuit, please visit Bernstein Liebhard LLP’s website. For more information, please call 800-511-5092.

*fda.gov/Drugs/DrugSafety/ucm343187.htm, FDA March 2013

**ismp.org/QuarterWatch/pdfs/2012Q3.pdf

***bmj.com/open-data/incretin#alternate; BMJ, June 10, 2010

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info (at) consumerinjurylawyers (dot) com

http://www.januvialawsuit2013.com/

For the original version on PRWeb visit: http://www.prweb.com/releases/januvia-lawsuit/januvia-pancreatic-cancer/prweb10947930.htm


Source: prweb



comments powered by Disqus